Innovent Biologics, IASO Bio strengthen collaboration with equity investment and licensing deal
Innovent Biologics, Inc. (HKEX: 01801), a globally recognized biopharmaceutical company, and IASO Biotechnology, a leader in innovative cell therapies and antibody products, have announced a ... Read More
FDA grants fast track designation to Innovent Biologics’ IBI343 in PDAC
Innovent Biologics, Inc. (HKEX: 01801), a prominent biopharmaceutical firm recognized for its innovative medicines, announced a pivotal advancement for its novel anti-CLDN18.2 ADC therapy, IBI343. ... Read More
Innovent Biologics reports significant clinical success with picankibart in psoriasis treatment
Innovent Biologics, Inc. (HKEX: 01801) has announced remarkable results from the CLEAR-1 Phase 3 registrational study of its novel drug, picankibart (R & D code: ... Read More
Innovent Biologics NDA for IBI311 in thyroid eye disease treatment gets priority review in China
Innovent Biologics, Inc. (HKEX: 01801), a leading biopharmaceutical company, announced that its New Drug Application (NDA) for IBI311, a pioneering treatment for Thyroid Eye Disease ... Read More
Innovent Biologics showcases promising preclinical data at AACR 2024
In a significant development for cancer research, Innovent Biologics, Inc. (HKEX: 01801), a leading biopharmaceutical company renowned for its innovative medicines in oncology, cardiovascular and ... Read More
Innovent Biologics announces positive Phase 2 results for Efdamrofusp Alfa in nAMD
In an important development for the treatment of neovascular age-related macular degeneration (nAMD), Innovent Biologics, Inc., a leading biopharmaceutical company, has announced successful results from ... Read More
RemeGen, Innovent Biologics to collaborate on clinical trials for combination therapies with ADCs
RemeGen, a commercial-stage Chinese biotechnology firm, and Innovent Biologics have announced their collaboration in a clinical research and supply agreement. This partnership focuses on conducting ... Read More
Innovent Biologics’ olverembatinib gets Chinese breakthrough therapy status in SDH-deficient GIST
Innovent Biologics has been granted breakthrough therapy designation (BTD) for olverembatinib from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). ... Read More
Innovent Biologics, Sanofi to expedite development of cancer drugs in China
Chinese biopharma company Innovent Biologics and French pharma giant Sanofi have entered into a partnership that aims to bring innovative drugs to patients in China ... Read More
FDA rejects Lilly’s sintilimab as first line treatment of NSCLC
The US Food and Drug Administration (FDA) has rejected the biologics license application (BLA) of Eli Lilly and Company (Lilly)’s sintilimab injection in nonsquamous non-small ... Read More